跳至主要内容
临床试验/NCT01529944
NCT01529944已完成3 期

Genetic Testing of Noonan Subjects Previously Treated With Norditropin® in the GHNOO-1658 Trial

Novo Nordisk A/S0 个研究点目标入组 22 人开始时间: 2008年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
22
主要终点
Change in height SDS (Standard Deviation Score) (referenced to normal population)

研究概览

简要总结

This trial is conducted in Europe. The aim of this trial is to obtain the PTPN11 mutation status and investigate the impact of the PTPN11 mutation status on the effect of somatropin (Norditropin®) by use of data obtained in the GHNOO-1658 trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Participation in the GHNOO-1658 trial
  • Subject has completed genetic testing of PTPN11 mutation

排除标准

  • 未提供

研究组 & 干预措施

Low dose 33 mcg/kg/day

Experimental

干预措施: somatropin (Drug)

High dose 66 mcg/kg/day

Experimental

干预措施: somatropin (Drug)

结局指标

主要结局

Change in height SDS (Standard Deviation Score) (referenced to normal population)

时间窗: From baseline until final height is reached

次要结局

  • Final height SDS (referenced to normal population)(From baseline until final height is reached)
  • Final height SDS (referenced to Noonan population)(From baseline until final height is reached)
  • Change in height SDS (referenced to Noonan population)(From baseline until final height is reached)
  • Number of subjects with final height SDS above - 2SDS (reference to normal population)(When final height is reached)
  • Proportion of subjects with final height SDS above - 2SDS (reference to normal population)(When final height is reached)
  • Adverse events(From baseline until final height is reached)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验